Carrier Status for the Common R501X and 2282del4 Filaggrin Mutations Is Not Associated with Hearing Phenotypes in 5377 Children from the ALSPAC Cohort Authors: Santiago Rodriguez, Amanda J. Hall, Raquel Granell, W. H. Irwin McLean, Alan D. Irvine, Colin N. A. Palmer, George Davey Smith, John Henderson, Ian N. M. Day Published: 2009, PLOS ONE DOI: 10.1371/journal.pone.0005784 ABSTRACT Filaggrin is a major protein in the epidermis. Several mutations in the filaggrin gene ( FLG ) have been associated with a number of conditions. Filaggrin is expressed in the tympanic membrane and could alter its mechanical properties, but the relationship between genetic variation in FLG and hearing has not yet been tested. We examined whether loss-of function mutations R501X and 2282del4 in the FLG gene affected hearing in children. Twenty eight hearing variables representing five different aspects of hearing at age nine years in 5,377 children from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort were tested for association with these mutations. No evidence of association was found between R501X or 2282del4 (or overall FLG mutation carrier status) and any of the hearing phenotypes analysed. In conclusion, carrier status for common filaggrin mutations does not affect hearing in children. INTRODUCTION Filaggrin ( fil ament agg regation prote in ) is a major protein in the cornified envelope of the epidermis and is involved in maintaining the skin barrier [1] , [2] . The filaggrin gene ( FLG ) in humans encodes a polyprotein precursor (profilaggrin) which, after post-translational processing, results in several individual filaggrin polypeptides [3] . Filaggrin has been linked to several clinical phenotypes, with filaggrin mutations being directly associated with the cause, susceptibility to, or modification of the clinical expression of several diseases including dermatological disorders [2] . Common mutations in FLG have been implicated in the causation of ichthyosis vulgaris and appear to be a major risk factor for atopic dermatitis, asthma associated with atopic dermatitis, eczema, sensitization to grass, house dust mite and cat dander, and sensitization to multiple allergens [2] , [4] , [5] . Two of the most studied mutations (R501X and 2282del4) are common in populations of European ancestry [6] . Both R501X and 2282del4 are loss-of function mutations leading to truncation of filaggrin translation by creating premature termination codons [7] . Both mutations have a complex role both in Mendelian disease and in complex diseases. An example is ichthyosis vulgaris. R501X and 2282del4 have been suggested to be the cause of ichthyosis vulgaris in 15 families and isolated cases, acting in a semidominant fashion with incomplete penetrance [7] . Homozygotes for either mutation or compound heterozygous are severely affected, with heterozygotes only mildy affected [7] . Additional reports confirmed the role of R501X and 2282del4 on ichthyosis vulgaris ( [8] for review). One of these studies [9] showed that heterozygous individuals were also severely affected, suggesting that additional mutations might be present in these patients. It has been shown that loss or reduction of filaggrin leads to impaired keratinization and defective skin barrier [7] . In fact, although it has not been pursued in the context of filaggrin mutations, filaggrin is also expressed in the tympanic membrane, where it is involved in the soft keratinization of the epidermal layer [10] . Therefore, FLG mutations could affect hearing. In addition, filaggrin has been localised immunohistochemically in middle ear cholesteatoma in humans [11] , this condition leading to an alteration of epidermal differentiation in middle ear [12] . Expression of FLG in these locations affecting the cornified envelope of the tympanic epidermis has the potential to influence hearing. The high prevalence of FLG mutations could reflect chance, but selective advantage through a trait such as hearing is another possibility. We hypothesized that such changes would affect air but not bone conduction as they affect tympanic membrane and not neural mechanisms. Clinical evidence available relates impaired keratinization to the filaggrin mutations R501X and 2282del4. To date, there has been no consideration of the possible effects with respect to filaggrin expression in the tympanic membrane. Based on this evidence we tested whether carrier status for a single copy of these mutations is a risk or protective factor for hearing loss/enhanced hearing in an epidemiological survey of 5,377 UK children with detailed phenotypic information for a range of hearing phenotypes. MATERIALS AND METHODS ALSPAC is a longitudinal, population-based birth cohort study that recruited 14,541 pregnant women residing in Avon, United Kingdom, with expected dates of delivery between April 1, 1991, and December 31, 1992. There were 14,062 liveborn children. The study protocol has been described previously [13] , [14] and further details are available on the ALSPAC Web site ( http://www.bris.ac.uk/alspac ). Ethical approval for all aspects of data collection was obtained from the ALSPAC Law and Ethics Committee (institutional review board 00003312). Written informed consent for the study was obtained. GENOTYPING Genotyping was done as previously described [4] . In brief, R501X and 2282del4 were genotyped with the TaqMan allelic discrimination assays (Applied Biosystems, Foster City, California) in 384-well plates. Double-checking with other technical approaches was performed in a substantial fraction of the samples, including all the identified homozygotes of both variants and all 2282del4 carriers. HEARING VARIABLES All study participants were invited to a research clinic at 9 years of age where five different hearing phenotypes were measured: hearing thresholds, transient evoked (TE) otoacoustic emission (OAE) amplitude, middle ear compliance and pressure. For these phenotypes, a total of 28 variables were analysed: hearing thresholds at five frequencies (0.5, 1, 2, 4 and 8 kHz) for air conduction and three frequencies (0.5, 1, 2 kHz) for bone conduction were measured. Tympanometry was used to measure middle ear compliance and middle ear pressure. TEOAE were evoked using a click stimulus of approximately 70 dB SPL (linear mode), and the response amplitude obtained for the total response and at frequency bands 1–4 kHz. All measures (except bone conduction thresholds) were obtained for both left and right ears. Since both mutations are inactivating mutations likely to have similar or identical effects and homozygotes and compound heterozygotes are rare, we also undertook a combined analysis (one degree of freedom) for each variable for FLG mutation carrier vs FLG mutation non-carrier. In addition to the analysis of each variable in all individuals, we tested whether each of the two mutations was associated with better versus worse hearing, using a cut off of < = 0 dB, both for hearing thresholds (right and left), and for bone conduction acute hearing thresholds. The effect of both mutations was also analysed by testing the association between each of the mutations and better versus worse cochlear function/middle ear transmission (worse cochlear function defined as the bottom quartile of the TEOAE amplitude distribution). We tested whether R501X or 2282del4 associated with bilateral middle ear effusion. Finally, we tested whether the filaggrin mutations associated with better hearing thresholds/TEOAE in cases with type A tympanograms (i.e. no middle ear effusion). STATISTICAL ANALYSES The associations between each of the two mutations and continuous variables were tested by means of one-way ANOVA analyses. Analyses involving the discrete variable bilateral middle ear effusion were performed by means of a Pearson χ 2 contingency test. All analyses were performed in SPSS ver. 15.0. RESULTS Complete data on genotypic data and at least one hearing variable were available for 5,377 children. There were no significant deviations from Hardy-Weinberg equilibrium for the mutations analysed (data not shown). The allele frequencies observed for R501X (0.021) and 2282del4 (0.023) are consistent with the allele frequencies observed in other studies (ranging from 0,021 to 0.041 for R501X, and from 0.005 to 0.019 for 2282del4) [9] . Tables 1 and 2 show the results from the association tests between each of the 28 variables analysed and R501X and 2282del4 respectively. There was no single nominal association between any of the 28 variables and R501X. For 2282del4, we found a nominal association (P = 0.0057) with air conduction hearing threshold level at 2 kHz on the right ear, but no association with the same hearing threshold for the left ear (P = 0.6855). The audiograms for two children homozygous for 2282del4 (who averaged right ear 2 kHz data which was significant; P = 0.0057) indicated an isolated right ear high threshold (35 dB) for one subject, whereas the other subject and both left ear values were near the population average. No association was found between the 28 variables and overall FLG mutation carrier vs non-carrier status ( Table 3 ). The results observed when considering the combined homozygote status association (compound heterozygous for both mutations plus homozygotes for 2282del4) were not remarkable (data not shown). There was no association with better versus worse hearing in either of the two mutations (data not shown). The analyses involving enhanced or diminished bone conduction did not show evidence of association with R501X (data not shown). A nominal association (P = 0.013) was found between the average bone conduction better versus worse hearing and 2282del4 but there was neither association nor evidence of any magnitude of difference by genotype for R501X. The analyses involving better versus worse cochlear function/middle ear transmission did not show evidence of association with R501X or 2282del4 (data not shown). Table 4 shows the contingency tables for the phenotype bilateral middle ear effusion for both R501X and 2282del4. There was no relationship between FLG mutations and middle ear effusion. The analysis of association between cases with type A tympanograms (i.e. no middle ear effusion) and the hearing variables showed no evidence of association with either mutation. Type A indicates normal middle ear function. Type B indicates middle ear effusion. Type C1 indicates slight negative middle ear pressure. Type C2 indicates negative middle ear pressure. Other indicates grommet, perforation, or type C2 tympanogram in at least one ear. Expected correspond to the expected contingency values were the null hypothesis is that the probabilities for each phenotype are independent of the mutation. TABLE: Effect of FLG R501X on 30 hearing variables as tested by one-way ANOVA tests. R501X N Mean SD F P Right ear Air conduction hearing threshold (dB HL) 0.5 kHz AA 4952 6.20 7.24 0.12 0.7328 Aa 219 6.37 6.75 1 kHz AA 5026 4.38 7.66 0.23 0.6291 Aa 223 4.13 6.61 2 kHz AA 5025 4.04 7.33 0.47 0.4914 Aa 223 3.70 5.80 4 kHz AA 5024 3.85 8.34 1.12 0.2908 Aa 223 3.25 7.90 8 kHz AA 4932 9.05 10.09 0.34 0.5583 Aa 218 8.65 9.10 Average 0.5, 1, 2, 4, 8 kHz AA 4926 5.47 6.34 0.33 0.5656 Aa 217 5.22 5.63 Left ear Air conduction hearing threshold (dB HL) 0.5 kHz AA 4954 6.48 7.30 0.02 0.8952 Aa 219 6.42 6.57 1 kHz AA 5025 4.52 7.67 2.49 0.1150 Aa 223 3.70 5.94 2 kHz AA 5023 4.24 7.53 0.76 0.3831 Aa 223 3.79 6.07 4 kHz AA 5022 4.68 8.60 0.63 0.4289 Aa 222 4.21 7.10 8 kHz AA 4931 9.16 10.36 0.69 0.4078 Aa 217 8.57 9.64 Average 0.5, 1, 2, 4, 8 kHz AA 4929 5.78 6.30 1.18 0.2781 Aa 216 5.31 5.19 Bone conduction hearing threshold (dB HL) 0.5 kHz AA 4859 −1.24 6.53 0.06 0.8069 Aa 215 −1.35 6.02 1 kHz AA 5000 −2.30 6.52 0.07 0.7956 Aa 222 −2.18 5.81 2 kHz AA 4868 0.95 7.26 0.20 0.6557 Aa 215 0.72 6.84 Average 0.5, 1, 2 kHz AA 4854 −0.89 5.38 0.01 0.9085 Aa 215 −0.93 5.01 Left ear TEOAE amplitude (dB SPL) 1 kHz AA 3865 −8.75 6.96 0.03 0.8677 Aa 164 −8.66 7.56 2 kHz AA 3899 −10.16 6.74 0.06 0.8092 Aa 165 −10.29 6.55 3 kHz AA 3893 −12.12 7.14 1.24 0.2661 Aa 166 −12.75 7.05 4 kHz AA 3906 −13.81 7.57 0.53 0.4680 Aa 166 −14.24 6.86 Total response AA 3917 9.62 5.69 0.05 0.8229 Aa 166 9.52 5.36 Right ear TEOAE amplitude (dB SPL) 1 kHz AA 3704 −7.66 6.91 2.63 0.1048 Aa 154 −6.73 7.20 2 kHz AA 3765 −9.04 6.52 3.50 0.0615 Aa 154 −8.04 6.11 3 kHz AA 3761 −11.44 7.18 0.08 0.7736 Aa 154 −11.27 6.76 4 kHz AA 3757 −13.54 7.42 0.60 0.4401 Aa 152 −14.01 7.07 Total response AA 3776 10.46 5.65 2.89 0.0894 Aa 154 11.25 5.46 Left ear Tympanometry Middle ear compliance (cm 3 ) AA 4785 0.64 0.42 1.72 0.1895 Aa 208 0.68 0.47 Middle ear pressure (daPa) AA 4796 −39.66 61.80 0.01 0.9430 Aa 207 −39.35 68.24 Right ear Tympanometry Middle ear compliance (cm 3 ) AA 4791 0.62 0.42 0.13 0.7215 Aa 206 0.63 0.43 Middle ear pressure (daPa) AA 4804 −39.47 61.42 0.14 0.7119 Aa 204 −37.84 64.31 TABLE: Effect of FLG 2282del4 on 30 hearing variables as tested by one-way ANOVA tests. 2282del4 N Mean SD F P Right ear Air conduction hearing threshold (dB HL) 0.5 kHz AA 4932 6.19 7.19 0.32 0.7243 Aa 238 6.55 7.83 aa 2 7.50 3.54 1 kHz AA 5010 4.32 7.53 2.29 0.1018 Aa 238 5.36 9.15 aa 2 7.50 3.54 2 kHz AA 5009 4.00 7.20 5.16 0.0057 Aa 238 4.39 8.43 aa 2 20.00 21.21 4 kHz AA 5008 3.80 8.30 0.51 0.5999 Aa 238 4.35 8.71 aa 2 2.50 3.54 8 kHz AA 4915 9.01 10.05 0.32 0.7282 Aa 234 9.53 10.09 aa 2 7.50 3.54 Average 0.5, 1, 2, 4, 8 kHz AA 4908 5.43 6.26 1.40 0.2456 Aa 234 6.06 7.29 aa 2 9.00 4.24 Left ear Air conduction hearing threshold (dB HL) 0.5 kHz AA 4934 6.48 7.27 0.05 0.9520 Aa 238 6.37 7.20 aa 2 7.50 3.54 1 kHz AA 5009 4.48 7.59 0.03 0.9664 Aa 238 4.60 8.01 aa 2 5.00 7.07 2 kHz AA 5007 4.20 7.44 0.38 0.6855 Aa 238 4.62 8.19 aa 2 5.00 0.00 4 kHz AA 5005 4.67 8.54 0.34 0.7106 Aa 238 4.50 8.59 aa 2 0.00 7.07 8 kHz AA 4913 9.15 10.32 0.10 0.9009 Aa 234 8.85 10.60 aa 2 10.00 0.00 Average 0.5, 1, 2, 4, 8 kHz AA 4910 5.75 6.23 0.01 0.9889 Aa 234 5.81 6.99 aa 2 5.50 3.54 Bone conduction hearing threshold (dB HL) 0.5 kHz AA 4840 −1.25 6.45 0.44 0.6461 Aa 233 −1.05 7.72 aa 2 2.50 10.61 1 kHz AA 4984 −2.30 6.39 0.58 0.5610 Aa 237 −2.19 8.27 aa 2 2.50 3.54 2 kHz AA 4849 0.93 7.17 0.34 0.7145 Aa 233 1.03 8.62 aa 2 5.00 7.07 Average 0.5, 1, 2 kHz AA 4835 −0.90 5.27 0.72 0.4870 Aa 233 −0.74 7.19 aa 2 3.33 2.36 Left ear TEOAE amplitude (dB SPL) 1 kHz AA 3838 −8.75 7.01 0.04 0.9621 Aa 191 −8.68 6.62 aa 1 −7.10 . 2 kHz AA 3871 −10.15 6.73 0.17 0.8443 Aa 193 −10.44 6.80 aa 1 −10.60 . 3 kHz AA 3867 −12.14 7.16 0.06 0.9387 Aa 192 −12.32 6.63 aa 1 −12.70 . 4 kHz AA 3880 −13.82 7.56 0.15 0.8629 Aa 192 −13.94 7.11 aa 1 −17.60 . Total response AA 3890 9.63 5.68 0.10 0.9026 Aa 193 9.45 5.50 aa 1 8.60 . Right ear TEOAE amplitude (dB SPL) 1 kHz AA 3668 −7.62 6.93 0.04 0.9637 Aa 190 −7.59 6.86 aa 1 −5.80 . 2 kHz AA 3727 −9.00 6.52 0.00 0.9970 Aa 192 −9.00 6.18 aa 1 −9.50 . 3 kHz AA 3722 −11.38 7.17 2.23 0.1074 Aa 193 −12.42 6.90 aa 1 −6.00 . 4 kHz AA 3716 −13.54 7.41 0.36 0.6982 Aa 193 −13.85 7.28 aa 1 −8.80 . Total response AA 3738 10.50 5.66 0.17 0.8470 Aa 192 10.29 5.39 aa 1 11.90 . Left ear Tympanometry Middle ear compliance (cm 3 ) AA 4767 0.64 0.42 0.22 0.7987 Aa 225 0.65 0.40 aa 2 0.55 0.07 Middle ear pressure (daPa) AA 4776 −39.73 62.29 0.32 0.7292 Aa 226 −37.96 57.50 aa 2 −10.00 14.14 Right ear Tympanometry Middle ear compliance (cm 3 ) AA 4768 0.62 0.42 1.60 0.2028 Aa 228 0.67 0.44 aa 2 0.45 0.07 Middle ear pressure (daPa) AA 4780 −39.37 61.61 0.14 0.8712 Aa 227 −40.00 60.16 aa 2 −17.50 10.61 TABLE: Effect of carrier (1) ( FLG R501X or FLG 2282del4) versus non-carrier (0) status on 30 hearing variables as tested by one-way ANOVA tests. Status N Mean SD F P Right ear Air conduction hearing threshold (dB HL) 0.5 kHz 0 4716 6.18 7.21 0.62 0.4308 1 455 6.46 7.32 1 kHz 0 4790 4.33 7.57 1.42 0.2333 1 459 4.77 8.05 2 kHz 0 4789 4.02 7.26 0.14 0.7041 1 459 4.15 7.41 4 kHz 0 4788 3.83 8.31 0.00 0.9926 1 459 3.82 8.35 8 kHz 0 4700 9.03 10.09 0.02 0.8892 1 450 9.10 9.63 Average 0.5, 1, 2, 4, 8 kHz 0 4694 5.44 6.28 0.56 0.4543 1 449 5.67 6.56 Left ear Air conduction hearing threshold (dB HL) 0.5 kHz 0 4718 6.48 7.31 0.04 0.8508 1 455 6.42 6.90 1 kHz 0 4789 4.51 7.66 0.58 0.4454 1 459 4.23 7.08 2 kHz 0 4787 4.21 7.50 0.02 0.8981 1 459 4.26 7.25 4 kHz 0 4786 4.69 8.60 0.71 0.3990 1 458 4.33 7.91 8 kHz 0 4699 9.18 10.35 0.86 0.3545 1 449 8.71 10.13 Average 0.5, 1, 2, 4, 8 kHz 0 4697 5.77 6.27 0.36 0.5510 1 448 5.59 6.20 Bone conduction hearing threshold (dB HL) 0.5 kHz 0 4628 −1.25 6.47 0.05 0.8241 1 446 −1.18 6.93 1 kHz 0 4765 −2.31 6.42 0.31 0.5772 1 457 −2.13 7.19 2 kHz 0 4637 0.94 7.18 0.01 0.9038 1 446 0.90 7.82 Average 0.5, 1, 2 kHz 0 4623 −0.90 5.28 0.14 0.7128 1 446 −0.80 6.22 Left ear TEOAE amplitude (dB SPL) 1 kHz 0 3677 −8.75 6.98 0.02 0.8939 1 352 −8.70 7.08 2 kHz 0 3709 −10.14 6.73 0.45 0.5047 1 355 −10.39 6.71 3 kHz 0 3704 −12.11 7.17 1.30 0.2538 1 355 −12.56 6.83 4 kHz 0 3717 −13.80 7.59 0.58 0.4452 1 355 −14.12 7.01 Total response 0 3727 9.64 5.70 0.31 0.5792 1 356 9.46 5.45 Right ear TEOAE amplitude (dB SPL) 1 kHz 0 3515 −7.66 6.91 1.46 0.2271 1 343 −7.19 7.02 2 kHz 0 3574 −9.04 6.54 1.54 0.2153 1 345 −8.58 6.16 3 kHz 0 3569 −11.39 7.19 1.60 0.2060 1 346 −11.90 6.87 4 kHz 0 3565 −13.52 7.42 0.77 0.3797 1 344 −13.89 7.19 Total response 0 3585 10.47 5.67 0.64 0.4242 1 345 10.72 5.44 Left ear Tympanometry Middle ear compliance (cm 3 ) 0 4562 0.64 0.42 1.64 0.2007 1 431 0.66 0.44 Middle ear pressure (daPa) 0 4572 −39.71 62.01 0.06 0.8113 1 431 −38.97 62.74 Right ear Tympanometry Middle ear compliance (cm 3 ) 0 4565 0.62 0.42 2.19 0.1389 1 432 0.65 0.44 Middle ear pressure (daPa) 0 4579 −39.44 61.49 0.02 0.8934 1 429 −39.02 62.08 TABLE: Effect of FLG R501X and 2282del4 on bilateral middle ear effusion. R501X 2282del4 AA Aa AA Aa aa Bilateral A Observed 3881 162 3856 186 2 Expected 3874.00 169.00 3861.22 181.25 1.53 Bilateral B Observed 62 2 63 1 0 Expected 61.32 2.68 61.11 2.87 0.02 Bilateral C1 Observed 121 3 118 6 0 Expected 118.82 5.18 118.40 5.56 0.05 Bilateral C2 Observed 58 5 61 2 0 Expected 60.37 2.63 60.15 2.82 0.02 Unilateral B Observed 164 8 168 4 0 Expected 164.81 7.19 164.23 7.71 0.07 Other Observed 780 41 783 38 0 Expected 786.68 34.32 783.89 36.80 0.31 Pearson χ 2 P = 0.402 P = 0.937 DISCUSSION This work is the first analysis of two common filaggrin mutations (R501X and 2282del4) for possible effect on hearing phenotypes. It was undertaken in a large (N = 5,377) cohort of UK children. These children were analysed in detail for a large number of hearing variables when they were nine years old. We did not find any support for the hypothesis that FLG mutation carrier status, via known expression in the tympanic membrane, might affect hearing. Two instances of nominal association were found in our study. However, both instances may be the result of type-I error, since we conducted 140 tests. The correction for multiple testing results in a limit of P = 0.0004 to reject the null hypothesis for an α = 0.05, a limit well below the minimum P value observed in our study. Furthermore, these nominal associations were not consistent between the two different FLG mutations. Our study was well powered (N = 5,377). This reduces the chance of false negatives. Therefore, our conclusions of no effect of R501X and 2282del4 on hearing thresholds or on otoacoustic emissions are robust. The same applies to our results indicating no effect of FLG mutations on tympanic membrane compliance, middle ear pressure or incidence of middle ear effusion. However, our results derive from a UK sample of nine year old children. It remains possible that there might be genotype-dependent effects in other age ranges and populations. REFERENCES [1] McGrath JA Uitto J 2008 The filaggrin story: novel insights into skin-barrier function and disease. Trends Mol Med 14 20 27 [2] McGrath JA 2008 Filaggrin and the great epidermal barrier grief. Australas J Dermatol 49 67 73 [3] Kinley-Grant LJ Idler WW Bernstein IA Parry DA Cannizzaro L 1989 Characterization of a cDNA clone encoding human filaggrin and localization of the gene to chromosome region 1q21. Proc Natl Acad Sci U S A 86 4848 4852 [4] Henderson J Northstone K Lee SP Liao H Zhao Y 2008 The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. J Allergy Clin Immunol 121 872 877 [5] Palmer CN Irvine AD Terron-Kwiatkowski A Zhao Y Liao H 2006 Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38 441 446 [6] Sandilands A Terron-Kwiatkowski A Hull PR O'Regan GM Clayton TH 2007 Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet 39 650 654 [7] Smith FJ Irvine AD Terron-Kwiatkowski A Sandilands A Campbell LE 2006 Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 38 337 342 [8] Hoffjan S Stemmler S 2007 On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. Br J Dermatol 157 441 449 [9] Gruber R Janecke AR Fauth C Utermann G Fritsch PO 2007 Filaggrin mutations p.R501X and c.2282del4 in ichthyosis vulgaris. Eur J Hum Genet 15 179 184 [10] Broekaert D 1995 The tympanic membrane: a biochemical updating of structural components. Acta Otorhinolaryngol Belg 49 127 137 [11] Chao WY Huang CC 1989 Localization of filaggrin in human middle ear cholesteatoma. Acta Otolaryngol 107 249 253 [12] Stammberger M Bujia J Kastenbauer E 1995 Alteration of epidermal differentiation in middle ear cholesteatoma. Am J Otol 16 527 531 [13] Jones RW Ring S Tyfield L Hamvas R Simmons H 2000 A new human genetic resource: a DNA bank established as part of the Avon longitudinal study of pregnancy and childhood (ALSPAC). Eur J Hum Genet 8 653 660 [14] Golding J Pembrey M Jones R 2001 ALSPAC–the Avon Longitudinal Study of Parents and Children. I. Study methodology. Paediatr Perinat Epidemiol 15 74 87